Belgian REITS Stock News

It's been a good week for Anheuser-Busch InBev SA/NV ( EBR:ABI ) shareholders, because the company has just released...

Shareholders might have noticed that KBC Group NV ( EBR:KBC ) filed its yearly result this time last week. The early...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

If you are wondering whether Umicore is still attractively priced after a volatile few years, this article will walk through what the current share price might imply about value. Over the last year, the share price is up 102.8%, even though the 7 day and 30 day returns are 3.2% and 1.8% declines and the 3 year and 5 year returns are 36.6% and 56.1% declines, with the stock most recently closing at €19.05. These moves sit against a backdrop of ongoing attention on Umicore's role in materials...

Anheuser-Busch InBev (ENXTBR:ABI) has wrapped up FY 2025 with fourth quarter revenue of about US$15.6b and basic EPS of US$0.99, rounding out a year where trailing 12 month revenue reached roughly US$59.3b and EPS came in at US$3.45. Over the past few quarters, revenue has moved from US$14.8b in Q4 2024 to US$15.0b in Q2 2025 and US$15.1b in Q3 2025, while quarterly EPS has ranged between US$0.53 and US$1.08, setting up a picture of higher trailing profitability alongside a net profit margin...

Banqup Group SA ( EBR:BANQ ) shareholders would be excited to see that the share price has had a great month, posting a...

BNP Paribas Asset Management has disclosed crossing the 3% legal threshold of direct voting rights in Umicore. The disclosure reflects an increased stake that now exceeds the mandatory reporting level for shareholder voting power. Umicore (ENXTBR:UMI) is trading at €18.8, with the share price up 81.3% over the past year, while longer term returns over 3 and 5 years show declines of 37.6% and 55.1% respectively. This mix of strong recent performance and weaker multi year returns gives a...

Econocom Group (ENXTBR:ECONB) closed FY 2025 with second half revenue of €1.5b and net income from continuing operations of €34.5m, while trailing twelve month net income from continuing operations reached €53.2m. The company has seen half year revenue move from €1.4b in H2 2024 to €1.5b in H2 2025, with trailing twelve month revenue rising from €2.7b to €2.9b over the same comparison window. With net profit margins running at 1.8% over the last year and earnings growth expectations in focus,...

Key Insights Elia Group's significant private companies ownership suggests that the key decisions are influenced by...

It's been a good week for Lotus Bakeries NV ( EBR:LOTB ) shareholders, because the company has just released its latest...

If you have been wondering whether Anheuser-Busch InBev shares are offering good value at current levels, this article walks through what the numbers are actually saying about the stock. The share price recently closed at US$63.66, with reported returns of 4.2% over 7 days, 12.6% over 30 days, 17.0% year to date, 32.3% over 1 year, 20.1% over 3 years, and 23.4% over 5 years. These figures provide useful context before assessing what the business might be worth. Recent coverage around...

Lotus Bakeries (ENXTBR:LOTB) has wrapped up FY 2025 with second half revenue of €697.7 million, basic EPS of €114.31 and net income of €92.9 million, while trailing twelve month revenue sits at about €1.4 billion with EPS of €212.06. The company has seen revenue move from €632.7 million in the second half of 2024 to €657.3 million in the first half of 2025 and €697.7 million in the second half of 2025. EPS over the same periods stepped from €99.12 to €97.74 and then €114.31, setting up a...

Key Insights Significant control over Groupe Bruxelles Lambert by private companies implies that the general public has...

Key Insights Using the 2 Stage Free Cash Flow to Equity, Umicore fair value estimate is €29.83 Umicore's €19.68 share...

It's been a sad week for Melexis NV ( EBR:MELE ), who've watched their investment drop 16% to €53.25 in the week since...

Orange Belgium (ENXTBR:OBEL) FY 2025 Earnings Snapshot Orange Belgium (ENXTBR:OBEL) has just reported its FY 2025 numbers with first half revenue of €962.7 million and basic EPS of €0.04, alongside trailing 12 month revenue of €1.96 billion and EPS of €0.61 that frame the latest run rate. The company recorded revenue of €977.5 million in the first half of 2024 and €1,016.2 million in the second half of 2024, while EPS moved from a loss of €0.20 to a profit of €0.56, before landing at €0.04 in...

Melexis NV ( EBR:MELE ) has announced that it will pay a dividend of €1.68 per share on the 21st of May. This makes the...

Argenx's Vyvgart is significantly outperforming expectations, with recent sales figures pointing to stronger than anticipated demand. The company is preparing for major Phase 3 trial readouts that are expected to clarify the potential of its broader pipeline. These developments are drawing attention from healthcare investors who view Vyvgart as an important contributor to fund performance. argenx (ENXTBR:ARGX) is drawing fresh interest as Vyvgart's performance adds weight to its current...

Key Insights Banqup Group's significant individual investors ownership suggests that the key decisions are influenced...

Despite an already strong run, DEME Group NV ( EBR:DEME ) shares have been powering on, with a gain of 26% in the last...

UCB has received European Union approval for Kygevi to treat thymidine kinase 2 deficiency (TK2d) in patients whose disease began before age 12, marking the first EU-authorized therapy for this rare genetic condition. The decision builds on prior FDA approval and retrospective data showing a very large reduction in risk of death versus untreated TK2d patients, underscoring Kygevi’s medical significance for a small but highly underserved population. We’ll now examine how Kygevi’s first-in-EU...

With a price-to-earnings (or "P/E") ratio of 13x Colruyt Group N.V. ( EBR:COLR ) may be sending bullish signals at the...

In January, argenx reported continued momentum for its autoimmune drug VYVGART, as the US FDA accepted a priority review of a supplemental biologics license application to extend its use to adults with acetylcholine receptor antibody‑seronegative generalized myasthenia gravis, while the franchise continued to post strong global sales growth in 2025. This combination of regulatory progress and broader clinical ambitions, spanning indications like immune thrombocytopenia, myositis and...

Warehouses De Pauw (ENXTBR:WDP) has wrapped up FY 2025 with fourth quarter revenue of €135.6 million and basic EPS of €0.46. This sits against a trailing 12 month picture that includes €545.8 million of revenue and EPS of €1.54. Over recent periods, revenue has moved from €116.1 million and EPS of €0.57 in Q4 2024 to €135.6 million and EPS of €0.46 in Q4 2025. The trailing 12 month net profit margin is reported at 71.4% for the latest year compared with 61.5% a year earlier, and that margin...